Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 0395 • ACR Convergence 2025
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
Anna Sutton¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Among adults, higher BMI contributes to worse outcomes and reduced response to treatment in rheumatoid arthritis (RA), but this relationship is understudied among those…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
José Miguel Senabre¹, Lucia Otero², Jerusalén Calvo³, Vega Jovaní⁴, Javier Manero-Ruiz⁵, Rabadán Elena⁶, Eugenia Enriquez⁷, Yanira Pérez⁸, Alicia Garcia⁹, Francisca Sivera¹⁰, Olga Martínez¹¹, María Colazo Burlato¹², Diana Sueiro¹³, Fernando Sánchez-Alonso¹⁴ and Isabel Castrejón Fernández¹⁵, ¹Hospital Marina Baixa, Villajoyosa/Vila Joiosa, La, Comunidad Valenciana, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁵Hospital Miguel Servet, Zaragoza, Spain, ⁶Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ⁷Clínica Universidad de Navarra, Madrid, Spain, ⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ⁹Rheumatologist, La Laguna, Spain, ¹⁰Hospital General Universitario Elda, Elda, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ¹²Hospital Universitario de Burgos, Burgos, Spain, ¹³Complexo Hospitalario Universitario de Ourense, Ourense, ¹⁴Sociedad Española de Reumatología, Madrid, Spain, ¹⁵MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…
Abstract Number: 2577 • ACR Convergence 2025
Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
Liya Sisay Getachew¹, Xiaosong Wang², Zachary Wallace³, Naomi Patel⁴, Lauren O'Keeffe⁵, Madison Negron⁶, Grace Qian⁵, Alene Saavedra⁵, Kevin Mueller⁵, Natalie Davis⁷, Yijia Li⁸, Manish Choudhary⁵, Julie Boucau³, Brooke Leeman⁵, Gregory Edelstein⁵, Owen Glover³, Yumeko Kawano⁵, Rinki Deo⁵, Caitlin Marino³, Zahra Reynolds³, Karry Su³, Chase Mandell³, Eliza Passell³, Mamadou Barry³, Andrew Alexandrescu³, Dibya Ghimire³, Mriganka Mandal⁹, Tammy Vyas³, Sarah Hammond³, Jatin Vyas³, Jacob Lemieux³, Mark Siedner³, Amy Barczak³, Jonathan Li³ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Harvard Extension School, Medford, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸University of Pittsburgh, Pittsburgh, ⁹Dana-Farber Cancer Institute, Boston
Background/Purpose: People with rheumatic diseases are at risk for acute and post-acute COVID-19 outcomes in part due to immunosuppressive medications. Those on B-cell depleting therapies…
Abstract Number: 1444 • ACR Convergence 2025
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Jeffrey Curtis¹, Genevieve Gauthier², Lara Fallon³, David Gruben³, You-Li Ling⁴, Matthew Brouillette³, Arne Yndestad⁵, Yu hong⁶ and Mona Kelkar⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ³Pfizer Inc, New York, NY, USA, New York, ⁴Pfizer Inc, New York, NY, USA, New York, NY, ⁵Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁶Genesis Research Group, Hoboken, NJ, USA, New York
Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…
Abstract Number: 0202 • ACR Convergence 2025
Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Fahidah Alenzi¹, Hanan Alrayes², Khawla K Alghanim³, FEHAID ALANAZI⁴, Mohammed Attar⁵, Mansour Alazmi⁶, Suzan Attar⁷, Nisreen Alsherbeeni⁸, Azzam Alotaibi⁹ and Fayssal M Farahat¹⁰, ¹Associate Professor and Consultant Rheumatology, Department of Internal Medicine, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ²Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, ³Consultant Rheumatologist and lupus specialist, Department of Internal Medicine, Rheumatology Unit, King Fahad Military Medical Complex, Dhahran, Saudi Arabia, Dhahran, Saudi Arabia, ⁴King Khaled university Hospital, Riyadh, Saudi Arabia, ⁵Al hada armed forces hospital, Taif, Saudi Arabia, ⁶Internal Medicine and Rheumatology Consultant , Prince Mohammed Medical City, Aljouf , Saudi Arabia, Sakaka- Aljouf, Saudi Arabia, ⁷King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ⁸Consultant Internal Medicine & Infectious Disease, Infectious Disease Division Department of Medicine at Prince Sultan Military Medical City, Riyadh, Saudi Arabia, ⁹Consultant Internal Medicine, Allergy, and Immunology, Division of Allergy and Immunology, Department of Medicine at Prince Sultan Military Medical City, Riyadh, Saudi Arabia, ¹⁰Infection Prevention and Control Program, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, P.O. Box ²²⁴⁹⁰, Riyadh ¹¹⁴²⁶, Saudi Arabia; College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, P.O. Box ³⁶⁶⁰, Riyadh ¹¹⁴⁸¹, Saudi Arabia; King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, P.O. Box ³⁶⁶⁰, Riyadh ¹¹⁴⁸¹, Saudi Arabia, Riyadh, Saudi Arabia
Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of infections due to both immune system dysfunction and the use of immunosuppressive…
Abstract Number: 2373 • ACR Convergence 2025
Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
Rocio Gonzalez Molina¹, BEATRIZ JOVEN², Marta Llanes³, Vanesa Hernandez⁴, Manuel Jose Moreno⁵, Elena Blanco⁶, Carolina Marin⁷, Lourdes Mateo⁸, Meritxell Salles Lizarzaburu⁹, Martina Steiner¹⁰, Laura Nuño¹¹, Antonio Fernández-Nebro¹², raúl Veroz González¹³, ana Urruticoechea-Arana¹⁴, Evelin Cervantes¹⁵, emilio Giner¹⁶, Lola Fernandez de la fuente Burson¹⁷, Alba Erra¹⁸, Oscar Camacho¹⁹, Elisabet Garcia²⁰, Angeles Hernandez²¹, Janire Malave²², Laia Orpinell²³, Inmaculada Ros Vilamajo²⁴, Sonia Castro²⁵, Patricia Lopez Viejo²⁶, Luis Sarabia²⁷, Rosa María García Portales²⁸, Jorge Cabezon²⁹, Puerto Moreno Gil³⁰, Francisco Maceiras³¹, Daniel Pielfort³², Sabela Diaz-Castroverde³³, Manuel Cuervas-mons³³, Jose Pinto-Tasende³⁴, Santiago Muñoz³⁵ and Julio Ramirez³⁶, ¹Hospital Reina Sofía, Murcia, Spain, ²H. Universitario ¹² Octubre, Madrid, Spain, ³H Juan Ramón Jimenez, Huelva, Spain, ⁴Hospital Universitario Canarias, Tenerife, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, El Palmar Murcia, Spain, ⁶Hospital Virgen del Rocio, Sevilla, Spain, ⁷Hospital Infanta Leonor, Madrid, Madrid, Spain, ⁸Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ⁹Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ¹¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Rheumatology. Hospital de Mérida. Mérida, Spain., Mérida, Spain, ¹⁴Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ¹⁵Hospital Provincial de Pontevedra, Pontevedra, Spain, ¹⁶Hospital Royo Vilanova, Zaragoza, Spain, ¹⁷Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁸Hospital Vall d´Hebron, Barcelona, Spain, ¹⁹Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²⁰Hospital Mollet, Barcelona, Spain, ²¹Hospital Naval, A Coruña, Spain, ²²Hospital Virgen del Puerto, Caceres, Spain, ²³Hospital Universitari Sagrat Cor, Barcelona, Spain, ²⁴Hospital Son Llàtzer, Palma de Mallorca, Spain, ²⁵ALTHAIA Hospital Sant Joan de Deu, Barcelona, Spain, ²⁶Hospital Universitario Getafe, Getafe, Spain, ²⁷Complejo Hospitalario de Jaén, Jaén, Spain, ²⁸HOSP. UNIVERSITARIO VIRGEN DE LA VICTORIA, Malaga, Spain, ²⁹HOSP. PUNTA DE EUROPA, Algeciras, Spain, ³⁰HOSPITAL SAN PEDRO DE ALCANTARA, Caceres, Spain, ³¹HOSPITAL DO MEIXOEIRO, Vigo, Spain, ³²Hospital General Universitario de Toledo, Toledo, Spain, ³³Johnson and Johnson, Madrid, Spain, ³⁴Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ³⁶Clinic Barcelona Hospital Universitari, Barcelona, Catalonia, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease affecting joints, entheses, skin, nails, and spine. While treatment options have expanded, TNF inhibitors (TNFis) remain the…
Abstract Number: 1440 • ACR Convergence 2025
Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
MÜSLÜM FIRAT İKİKARDEŞ¹, EMRAH KOÇ¹, gEZMIS KIMYON², EMİNE DUYGU ERSOZLU¹ and TAYYIBE SALER¹, ¹ADANA SEHİR HASTANESİ, ADANA, Turkey, ²MUSTAFA KEMAL UNIVERSITY, HATAY, Turkey
Background/Purpose: We aimed to compare the demographic and clinical characteristics of the patients with axial spondyloarthritis (aSpA) receiving standard-dose versus tapered-dose biologic disease-modifying antirheumatic drugs…
Abstract Number: 0108 • ACR Convergence 2025
In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
Jesús Eduardo Martín Salazar¹, Clementina López Medina², Carlos Pérez Sánchez³, María Ángeles Puche-Larrubia⁴, Pedro Ortiz Buitrago⁵, María Dolores López-Montilla⁶, Iván Arias de la Rosa⁷, Laura Cuesta López⁸, Miriam Ruiz Ponce⁸, Antonio Barranco⁸, Laura Romero Zurita⁸, Elena Moreno-Caño⁹, Rafaela Ortega-Castro¹⁰, Jerusalén Calvo¹¹, M Carmen Abalos-Aguilera¹², Desiree Ruiz-Vilchez¹³, Chary López pedrera¹⁴, Alejandro Escudero Contreras¹¹, Eduardo Collantes estévez¹⁵ and Nuria Barbarroja¹⁶, ¹Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴Reina Sofia University Hospital, Granada, Spain, ⁵Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁶Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, ⁹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹¹IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹³Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease for which TNFα inhibitors are the standard first-line biologic therapy. Nonetheless, a significant proportion of patients…
Abstract Number: 2370 • ACR Convergence 2025
Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Punith Chirumamilla¹, Ravi Medarametla², Anjani Mahesh Kumar Cherukuri³, Sri Laxmi Priya Sunkara⁴, Pranathi Bandarupalli⁵, Rithish Nimmagadda⁶, Greeshma Erasani⁷, Pavana Sakhamuri⁸ and Stephen Lindsey⁹, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Guntur Medical College, Guntur, Andhra Pradesh, India, ⁴White river medical center, batesville, AR, ⁵Mercy St Vincent Medical Center, Toledo, OH, ⁶One Brooklyn Health, New York, NY, ⁷University of Missouri-Kansas city school of medicine, KCMO, MO, ⁸LSUHSC, Lafayette, LA, ⁹LSU Health Sciences Center-New Orleans, Baton Rouge, LA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated disease which involves joints, skin, and nails, leading to deformities, decreased function, lower quality of life, and…
Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…
Abstract Number: 0100 • ACR Convergence 2025
Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Beatriz Vellón-García¹, Gema Dolores García-Delgado², Adrián Llamas Urbano³, Yas Hanaee³, Pedro Ortiz Buitrago⁴, Christian Merlo⁵, Maria del carmen abalos-aguilera⁵, julio Manuel Martinez Moreno⁶, Iván Arias de la Rosa⁷, María Dolores López-Montilla⁸, Rafaela Ortega-Castro⁹, Jerusalén Calvo¹⁰, Lourdes Ladehesa¹¹, Clementina López Medina¹², María Ángeles Puche-Larrubia¹³, Nuria Barbarroja¹⁴, Eduardo Collantes estévez¹⁵, Alejandro Escudero-contreras⁵, Chary López pedrera¹⁶, Jose manuel Villalba¹⁷ and Carlos Pérez Sánchez¹⁸, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ³Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁶Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, ⁷IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, ⁸Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹⁰IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹¹IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ¹³Reina Sofia University Hospital, Granada, Spain, ¹⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁵Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ¹⁷Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
Abstract Number: 2364 • ACR Convergence 2025
Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Milad Heydari-Kamjani¹, Jennifer Murphy² and Marina Magrey³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with variable clinical presentation and treatment response. A subset of PsA patients are difficult to treat…
Abstract Number: 1372 • ACR Convergence 2025
Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are recommended for patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic or biologic disease-modifying antirheumatic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].